AAAtsuko Ashida

Atsuko Ashida

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Atsuko Ashida has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Persistent alteration of the skin microbiome in patients with skin rash after receiving EGFR inhibitor treatment

    by Atsuko Ashida, Shuta Tomida, Tokuro Iwabuchi, Yuki Sato, Yukiko Kiniwa, Ryuhei Okuyama

    The pathological mechanism responsible for EGFR inhibitor (EGFRI)‐induced skin rash remains unclear. Recent studies reveal associations between skin dysbiosis and skin inflammatory diseases. This study aimed to examine whether skin dysbiosis is associated with EGFRI‐induced skin rash. Bacterial swabs were taken from the forehead of 17 cancer patients at baseline and at several time points after EGFRIs initiation, as well as from 20 healthy controls. The skin microbiome was analysed using 16S rRNA sequencing. The severity of the skin rash was assessed using the rash grade. Skin surface parameters (pH, water capacitance, and sebum level) were also measured. Compared with baseline, the abundance of Cutibacterium acnes decreased in 13 of 15 cases, and that of Staphylococcus aureus, Corynebacterium spp., Staphylococcus epidermidis or Proteobacteria increased in 13 of 15 cases after EGFRIs initiation. Skin pH increased significantly in parallel with a decrease in water capacitance after EGFRI initiation. Also, the composition of the skin microbiome of patients with severe rash was significantly different from that of healthy controls. In addition, the skin dysbiosis did not return to baseline during EGFRIs treatment for >1 year. These longitudinal observations indicate that skin dysbiosis is associated with development of skin rash.


  • Dacarbazine as third-line treatment for malignant melanoma : Retrospective study of three cases

    by Kenta Nakamura, Atsuko Ashida, Reina Nakamura, Yukiko Kiniwa, Ryuhei Okuyama

    BRAF変異陰性の切除不能メラノーマの治療として,免疫チェックポイント阻害薬の抗PD-1/PD-L1抗体や抗CTLA-4抗体が選択されるが,それぞれの奏効率は30%と10%程度であり,過剰な自己免疫による副作用で治療継続が困難になる症例もある。今回,私たちは,そのような症例で,第三選択としてダカルバジンを使用したメラノーマの3症例を報告する。治療効果は,部分奏功1例,不変1例,進行1例であった。また,これらの3症例では,ダカルバジンの治療効果と血中のLDHや5-S-CDの値の変動が相関した。今後,症例を集積し,第三選択としてのダカルバジンの奏効率を報告し,治療効果を判定するマーカーとしてLDHや5-S-CDが有用であるか検討することが,メラノーマの治療選択に重要であると考える。


  • Open Access

    NADPH Oxidase 4 Contributes to Transformation Phenotype of Melanoma Cells by Regulating G2-M Cell Cycle Progression

    by Maki Yamaura, Junji Mitsushita, Shuichi Furuta, Yukiko Kiniwa, Atsuko Ashida, Yasuhumi Goto, Wei H. Shang, Makoto Kubodera, Masayoshi Kato, Minoru Takata, et al.

    Generation of reactive oxygen species (ROS) has been implicated in carcinogenic development of melanoma, but the underlying molecular mechanism has not been fully elucidated. We studied the expression and function of the superoxide-generating NADPH oxidase (Nox)4 in human melanoma cells. Nox4 was up-regulated in 13 of 20 melanoma cell lines tested. Silencing of Nox4 expression in melanoma MM-BP cells by small interfering RNAs decreased ROS production and thereby inhibited anchorage-independent cell growth and tumorigenecity in nude mice. Consistently, a general Nox inhibitor, diphenylene iodonium, and antioxidants vitamine E and pyrrolidine dithiocarbamate blocked cell proliferation of MM-BP cells. Flow cytometric analysis indicated that Nox4 small interfering RNAs and diphenylene iodonium induced G2-M cell cycle arrest, which was also observed with another melanoma cell line, 928mel. This was accompanied by induction of the Tyr-15 phosphorylated, inactive form of cyclin-dependent kinase 1 (a hallmark of G2-M checkpoint) and hyperphosphorylation of cdc25c leading to its increased binding to 14-3-3 proteins. Ectopic expression of catalase, a scavenger of ROS, also caused accumulation of cells in G2-M phase. Immunohistochemistry revealed that expression of Nox4 was detected in 31.0% of 13 melanoma patients samples, suggesting the association of Nox4 expression with some steps of melanoma development. The findings suggest that Nox4-generated ROS are required for transformation phenotype of melanoma cells and contribute to melanoma growth through regulation of G2-M cell cycle progression. [Cancer Res 2009;69(6):2647–54]